Table 1.
Patients’ Characteristics
| Characteristics (n=105) | |
|---|---|
| Age (years), median (IQR) | 72 (67–77) |
| Male sex, n (%) | 75 (71.4) |
| ECOG PS score, n (%) | |
| 0 | 64 (61.0) |
| 1 | 31 (29.5) |
| ≥2 | 10 (9.5) |
| Primary tumor site, n (%) | |
| Bladder | 42 (40.0) |
| Upper urinary tract | 41 (39.0) |
| Upper urinary tract + bladder | 22 (21.0) |
| Pure UC in histologic testing, n (%) | 85 (81.0) |
| Albumin (g/dL), median (IQR) | 3.8 (3.5–4.2) |
| LDH (U/L), median (IQR) | 200 (178–237) |
| Number of prior chemotherapy regimens, n (%) | |
| 1 | 84 (80.0) |
| 2 | 12 (11.4) |
| 3 | 9 (8.6) |
| Disease site (including primary organ), n (%) | |
| 1 organ | 47 (44.8) |
| 2 organs | 26 (24.8) |
| ≥3 organs | 32 (30.5) |
| Follow-up period (months), median (IQR) | 8.4 (4.1–15.7) |
| Progression free survival (months), median (95% CI) | 3.3 (2.8–5.5) |
| Overall survival (months), median (95% CI) | 13.7 (10.2–19.8) |
Abbreviations: IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group Performance Status; UC, urothelial carcinoma; LDH, lactate dehydrogenase; CI, confidence interval.